jRCT2051200119CompletedNot Applicable
Clinical Pharmacology Study of AK1830 (Drug-Drug Interaction Study in Healthy Men)
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Enrollment
- 20
- Primary Endpoint
- -
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
- Allocation
- Single Arm Study
- Intervention Model
- Single Assignment
- Primary Purpose
- Treatment Purpose
- Masking
- Open(masking Not Used)
Eligibility Criteria
- Ages
- 20age old over to 44age old under (—)
- Sex
- Male
Inclusion Criteria
- •The subjects will be individuals who meet all of the following criteria.
- •[1] Healthy men
- •[2] Individuals >=20 to <45 years of age at the time of informed consent
- •[3] Individuals who fully understand the details of the study and who are capable of providing written informed consent
Exclusion Criteria
- •Individuals meeting any of the following criteria will be excluded from the study.
- •[1] Past history of disease of kidney, liver, heart, brain, or other conditions considered unsuitable for this study
- •[2] Past history of disease or surgery that could affect absorption of the investigational product or designated concomitant drug
- •[3] Other protocol defined exclusion criteria could apply
Outcomes
Primary Outcomes
-
Plasma concentration of compound(s)
Secondary Outcomes
No secondary outcomes reported
Investigators
Similar Trials
Completed
Phase 1
Clinical Pharmacology Study of AK1830 (Drug-Drug Interaction Study in Healthy Men)JPRN-jRCT2051200119Shimizu Tomohito20
Completed
Not Applicable
Clinical Pharmacology Study of AK1830 (Drug-Drug Interaction Study in Healthy Men)jRCT2051200123Asahi Kasei Pharma Corporation40
Completed
Phase 1
Clinical Pharmacology Study of AK1830 (Drug-Drug Interaction Study in Healthy Men)JPRN-jRCT2051200123Shimizu Tomohito40
Unknown
Phase 3
A clinical pharmacological study of SK-0403Type 2 diabetes mellitusJPRN-jRCT2080221260SANWA KAGAKU KENKYUSHO CO.,LTD.20
Unknown
Phase 1
A phase I clinical pharmacology study of TAK-233 in healthy subjectsHealthy adult female subjectsJPRN-jRCT2080222396TAKEDA PHARMACEUTICAL COMPANY LTD.24